https://www.live-feeds.com/feed/novo-struggles-to-appease-restive-investors-with-consumer-plans-blockbuster-ambitionsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-struggles-to-appease-restive-investors-with-consumer-plans-blockbuster-ambitionshttps://www.live-feeds.com/feed/novo-struggles-to-appease-restive-investors-with-consumer-plans-blockbuster-ambitions#u81734Wed, 23 Sep 2026 20:15:51 +0000Novo Nordisk stock declined after the drugmaker unveiled a growth strategy to reduce reliance on Wegovy. The company aims to launch more than five blockbuster drugs by 2030 and is signaling increased merger and acquisition activity to bolster its pipeline. Despite these ambitions and new consumer plans, investors remain unconvinced by the lack of specific turnaround details. The CEO acknowledged that the company has more work to do to rebuild investor confidence and combat competition from Eli Lilly.Why it mattersWegovy has driven massive growth for Novo Nordisk, but the company now faces pres